Guggenheim Maintains Buy on Edgewise Therapeutics, Raises Price Target to $51

Benzinga · 07/06 14:09
Guggenheim analyst Debjit Chattopadhyay maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $41 to $51.